

Daily evidence digest

11 March 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Seroconversion in mild COVID-19, resistance in Delta variant following sotrovimab use, recombinant Deltamicon, antivirals vs Omicron BA.2

Peer reviewed journals featured:

- Observational studies on:
 - Seroconversion in children and adults with mild COVID-19 [here](#)
 - The effect of mRNA vaccine boosters against Omicron infection in Qatar [here](#)
 - The effects of weather and compliance with the first UK COVID-19 lockdown [here](#)
 - Hospitalisations and mortality from non-SARS-CoV-2 causes in the US [here](#)
 - The effects of decontamination treatments on N95 respirators [here](#)
- A modelling study on maintaining face mask use after achieving different COVID-19 vaccination coverage levels [here](#)
- Commentary on solving retention to support workforce recovery post-pandemic in the UK [here](#)

Letters and correspondence discussed:

- Resistance mutations in Delta variant after sotrovimab use [here](#)
- Persistent SARS-CoV-2 infection in asymptomatic young adults [here](#)
- Efficacy of antiviral agents against the Omicron subvariant BA.2 [here](#)

Pre-peer review articles featured:

- Culture and identification of a Deltamicon infection in southern France [here](#)
- Risk of myocarditis and pericarditis following COVID-19 vaccination in England and Wales [here](#)

Guidance and reports

- The World Health Organization published guidance on the use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)

News and blogs

- Once viewed as a promising COVID-19 treatment, convalescent plasma falls out of favour [here](#)
- Florida surgeon-general says state will be first not to recommend vaccination for children [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).